The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease

International Journal of Molecular Sciences

Volumn 14, Issue 7, 2013, Pages 13909-13930

  Kikuchi, Kiyoshi ^a,b   Tancharoen, Salunya ^a   Takeshige, Nobuyuki ^b   Yoshitomi, Munetake ^b   Morioka, Motohiro ^b   Murai, Yoshinaka ^b   Tanaka, Eiichiro ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease; Edaravone; Free radical scavenger

Indexed keywords

ALTEPLASE; AMLODIPINE; ARGATROBAN; FLUINDOSTATIN; NORPHENAZONE; OZAGREL;

ACUTE KIDNEY FAILURE; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BRAIN EDEMA; BRAIN INJURY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; HEART FAILURE; HEART INFARCTION; HEART INJURY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER DYSFUNCTION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; ANTIPYRINE; CARDIOVASCULAR DISEASES; FREE RADICAL SCAVENGERS; GENE EXPRESSION; HUMANS; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN SPECIES; STROKE;

EID: 84880249861     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140713909     Document Type: Review

References (150)

1. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012, 380, 2095-2128.
2. World Health Organization: Cardiovascular disease. Available online: http://www.who.int/cardiovascular_diseases/en/ (accessed on 14 April 2013).
3. O'Collins, V.E.; Macleod, M.R.; Donnan, G.A.; Horky, L.L.; van der Worp, B.H.; Howells, D.W. 1026 experimental treatments in acute stroke. Ann. Neurol. 2006, 59, 467-477.
4. The Lancet. Neuroprotection: The end of an era? Lancet 2006, 368, 1548.
5. The RANTTAS investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996, 27, 1453-1458.
6. Asano, T.; Takakura, K.; Sano, K.; Kikuchi, H.; Nagai, H.; Saito, I.; Tamura, A.; Ochiai, C.; Sasaki, T. Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: Results of a multicenter, placebo-controlled double-blind trial. J. Neurosurg. 1996, 84, 792-803.
7. Green, A.R.; Shuaib, A. Therapeutic strategies for the treatment of stroke. Drug. Discov. Today 2006, 11, 681-693.
8. Shuaib, A.; Lees, K.R.; Lyden, P.; Grotta, J.; Davalos, A.; Davis, S.M.; Diener, H.C.; Ashwood, T.; Wasiewski, W.W.; Emeribe, U. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 2007, 357, 562-571.
9. Van der Worp, H.B.; Kappelle, L.J.; Algra, A.; Bar, P.R.; Orgogozo, J.M.; Ringelstein, E.B.; Bath, P.M.; van Gijn, J. The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology 2002, 58, 133-135.
10. Myung, S.K.; Ju, W.; Cho, B.; Oh, S.W.; Park, S.M.; Koo, B.K.; Park, B.J. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: Systematic review and meta-analysis of randomised controlled trials. BMJ 2013, 346, f10.
11. Kikuchi, K.; Kawahara, K.; Miyagi, N.; Uchikado, H.; Kuramoto, T.; Morimoto, Y.; Tancharoen, S.; Miura, N.; Takenouchi, K.; Oyama, Y., et al. Edaravone: A new therapeutic approach for the treatment of acute stroke. Med. Hypothese 2010, 75, 583-585.
12. Kikuchi, K.; Kawahara, K.; Tancharoen, S.; Matsuda, F.; Morimoto, Y.; Ito, T.; Biswas, K.K.; Takenouchi, K.; Miura, N.; Oyama, Y., et al. The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J. Pharmacol. Exp. Ther. 2009, 329, 865-874.
13. Kikuchi, K.; Miura, N.; Kawahara, K.; Murai, Y.; Morioka, M.; Lapchak, P.; Tanaka, E. Edaravone (radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke (review). Biomed. Rep. 2013, 1, 7-12.
14. Kikuchi, K.; Tancharoen, S.; Matsuda, F.; Biswas, K.K.; Ito, T.; Morimoto, Y.; Oyama, Y.; Takenouchi, K.; Miura, N.; Arimura, N., et al. Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem. Biophys. Res. Commun. 2009, 390, 1121-1125.
15. Tanaka, E.; Niiyama, S.; Sato, S.; Yamada, A.; Higashi, H. Arachidonic acid metabolites contribute to the irreversible depolarization induced by in vitro ischemia. J. Neurophysiol. 2003, 90, 3213-3223.
16. Kikuchi, K.; Kawahara, K.; Uchikado, H.; Miyagi, N.; Kuramoto, T.; Miyagi, T.; Morimoto, Y.; Ito, T.; Tancharoen, S.; Miura, N., et al. Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. Exp. Ther. Med. 2011, 2, 771-775.
17. Kikuchi, K.; Miura, N.; Morimoto, Y.; Ito, T.; Tancharoen, S.; Miyata, K.; Kikuchi, C.; Iida, N.; Takeshige, N.; Uchikado, H., et al. Beneficial effects of the free radical scavenger edaravone (radicut) in neurologic diseases. J. Neurol. Neurophysiol. 2011, 1, 1-5.
18. Kikuchi, K.; Takeshige, N.; Miura, N.; Morimoto, Y.; Ito, T.; Tancharoen, S.; Miyata, K.; Kikuchi, C.; Iida, N.; Uchikado, H., et al. Beyond free radical scavenging: Beneficial effects of edaravone (radicut) in various diseases (review). Exp. Ther. Med. 2012, 3, 3-8.
19. Kikuchi, K.; Uchikado, H.; Miyagi, N.; Morimoto, Y.; Ito, T.; Tancharoen, S.; Miura, N.; Miyata, K.; Sakamoto, R.; Kikuchi, C. et al. Beyond neurological disease: New targets for edaravone (review). Int. J. Mol. Med. 2011, 28, 899-906.
20. Tsujita, K.; Shimomura, H.; Kawano, H.; Hokamaki, J.; Fukuda, M.; Yamashita, T.; Hida, S.; Nakamura, Y.; Nagayoshi, Y.; Sakamoto, T., et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am. J. Cardiol. 2004, 94, 481-484.
21. Watanabe, T.; Yuki, S.; Egawa, M.; Nishi, H. Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 1994, 268, 1597-1604.
22. Yamamoto, T.; Yuki, S.; Watanabe, T.; Mitsuka, M.; Saito, K.I.; Kogure, K. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral Ischemia. Brain Res. 1997, 762, 240-242.
23. Inokuchi, Y.; Imai, S.; Nakajima, Y.; Shimazawa, M.; Aihara, M.; Araie, M.; Hara, H. Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo. J. Pharmacol. Exp.Ther. 2009, 329, 687-698.
24. Sommani, P.; Arai, T.; Yamashita, K.; Miyoshi, T.; Mori, H.; Sasada, M.; Makino, K. Effects of edaravone on singlet oxygen released from activated human neutrophils. J. Pharmacol. Sci. 2007, 103, 117-120.
25. Higashi, Y.; Jitsuiki, D.; Chayama, K.; Yoshizumi, M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov. 2006, 1, 85-93.
26. Yamamoto, Y.; Kuwahara, T.; Watanabe, K.; Watanabe, K. Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep. 1996, 2, 333-338.
27. Yoshida, H.; Sasaki, K.; Namiki, Y.; Sato, N.; Tada, N. Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis 2005, 179, 97-102.
28. Tosaka, M.; Hashiba, Y.; Saito, N.; Imai, H.; Shimizu, T.; Sasaki, T. Contractile responses to reactive oxygen species in the canine basilar artery in vitro: Selective inhibitory effect of MCI-186, a new hydroxyl radical scavenger. Acta Neurochir. 2002, 144, 1305-1310.
29. Takayasu, Y.; Nakaki, J.; Kawasaki, T.; Koda, K.; Ago, Y.; Baba, A.; Matsuda, T. Edaravone, a Radical scavenger, inhibits mitochondrial permeability transition pore in rat brain. J. Pharmacol. Sci. 2007, 103, 434-437.
30. Kawai, H.; Nakai, H.; Suga, M.; Yuki, S.; Watanabe, T.; Saito, K.I. Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 1997, 281, 921-927.
31. Zhang, N.; Komine-Kobayashi, M.; Tanaka, R.; Liu, M.; Mizuno, Y.; Urabe, T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005, 36, 2220-2225.
32. Xiao, B.; Bi, F.F.; Hu, Y.Q.; Tian, F.F.; Wu, Z.G.; Mujlli, H.M.; Ding, L.; Zhou, X.F. Edaravone neuroprotection effected by suppressing the gene expression of the fas signal pathway following transient focal ischemia in rats. Neurotox. Res. 2007, 12, 155-162.
33. Amemiya, S.; Kamiya, T.; Nito, C.; Inaba, T.; Kato, K.; Ueda, M.; Shimazaki, K.; Katayama, Y. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur. J. Pharmacol. 2005, 516, 125-130.
34. Qi, X.; Okuma, Y.; Hosoi, T.; Nomura, Y. Edaravone protects against hypoxia/ischemia-induced endoplasmic reticulum dysfunction. J. Pharmacol. Exp. Ther. 2004, 311, 388-393.
35. Yung, H.W.; Korolchuk, S.; Tolkovsky, A.M.; Charnock-Jones, D.S.; Burton, G.J. Endoplasmic reticulum stress exacerbates ischemia-reperfusion-induced apoptosis through attenuation of akt protein synthesis in human choriocarcinoma cells. FASEB J. 2007, 21, 872-884.
36. Jin, Y.J.; Mima, T.; Raicu, V.; Park, K.C.; Shimizu, K. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci. Res. 2002, 43, 75-79.
37. Ishikawa, A.; Yoshida, H.; Metoki, N.; Toki, T.; Imaizumi, T.; Matsumiya, T.; Yamashita, K.; Taima, K.; Satoh, K. Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia. Neurosci. Res. 2007, 59, 406-412.
38. Barone, F.C.; Feuerstein, G.Z. Inflammatory mediators and stroke: New opportunities for novel therapeutics. J. Cereb. Blood Flow MeTable 1999, 19, 819-834.
39. Baird, A.E.; Benfield, A.; Schlaug, G.; Siewert, B.; Lovblad, K.O.; Edelman, R.R.; Warach, S. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann. Neurol. 1997, 41, 581-589.
40. Bemeur, C.; Ste-Marie, L.; Desjardins, P.; Vachon, L.; Butterworth, R.F.; Hazell, A.S.; Montgomery, J. Dehydroascorbic acid normalizes several markers of oxidative stress and inflammation in acute hyperglycemic focal cerebral ischemia in the rat. Neurochem. Int. 2005, 46, 399-407.
41. Block, F.; Dihne, M.; Loos, M. Inflammation in areas of remote changes following focal brain lesion. Prog. Neurobiol. 2005, 75, 342-365.
42. Bramlett, H.M.; Dietrich, W.D. Pathophysiology of cerebral ischemia and brain trauma: Similarities and DIFFERENCES. J. Cereb. Blood Flow MeTable 2004, 24, 133-150.
43. Khan, M.; Sekhon, B.; Jatana, M.; Giri, S.; Gilg, A.G.; Sekhon, C.; Singh, I.; Singh, A.K. Administration of n-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J. Neurosci. Res. 2004, 76, 519-527.
44. Kim, J.B.; Yu, Y.M.; Kim, S.W.; Lee, J.K. Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious neuroprotection in the postischemic brain. Brain Res. 2005, 1060, 188-192.
45. Matsui, T.; Mori, T.; Tateishi, N.; Kagamiishi, Y.; Satoh, S.; Katsube, N.; Morikawa, E.; Morimoto, T.; Ikuta, F.; Asano, T. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part I: Enhanced astrocytic synthesis of s-100beta in the periinfarct area precedes delayed infarct expansion. J. Cereb. Blood Flow MeTable 2002, 22, 711-722.
46. Wen, Y.; Yang, S.; Liu, R.; Perez, E.; Yi, K.D.; Koulen, P.; Simpkins, J.W. Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res. 2004, 1008, 147-154.
47. Suzuki, Y.J.; Forman, H.J.; Sevanian, A. Oxidants as stimulators of signal transduction. Free Radic. Biol. Med. 1997, 22, 269-285.
48. Goldstein, R.S.; Gallowitsch-Puerta, M.; Yang, L.; Rosas-Ballina, M.; Huston, J.M.; Czura, C.J.; Lee, D.C.; Ward, M.F.; Bruchfeld, A.N.; Wang, H., et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006, 25, 571-574.
49. Huang, J.M.; Hu, J.; Chen, N.; Hu, M.L. Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. J. Crit. Care 2012, in press.
50. Schulze, J.; Zierath, D.; Tanzi, P.; Cain, K.; Shibata, D.; Dressel, A.; Becker, K. Severe stroke induces long-lasting alterations of high-mobility group box 1. Stroke 2013, 44, 246-248.
51. Yagi, K.; Kitazato, K.T.; Uno, M.; Tada, Y.; Kinouchi, T.; Shimada, K.; Nagahiro, S. Edaravone, a free radical scavenger, inhibits mmp-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009, 40, 626-631.
52. Yamashita, T.; Kamiya, T.; Deguchi, K.; Inaba, T.; Zhang, H.; Shang, J.; Miyazaki, K.; Ohtsuka, A.; Katayama, Y.; Abe, K. dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J. Cereb. Blood Flow MeTable 2009, 29, 715-725.
53. Wang, C.X.; Shuaib, A. Neuroprotective effects of free radical scavengers in stroke. Drugs Aging 2007, 24, 537-546.
54. Adams, H.P., Jr.; del Zoppo, G.; Alberts, M.J.; Bhatt, D.L.; Brass, L.; Furlan, A.; Grubb, R.L.; Higashida, R.T.; Jauch, E.C.; Kidwell, C. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007, 115, e478-e534.
55. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, Placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. 2003, 15, 222-229.
56. Naritomi, H.; Moriwaki, H.; Metoki, N.; Nishimura, H.; Higashi, Y.; Yamamoto, Y.; Yuasa, H.; Oe, H.; Tanaka, K.; Saito, K., et al. Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: A randomized controlled pilot study. Drugs R D 2010, 10, 155-163.
57. Shinohara, Y.; Saito, I.; Kobayashi, S.; Uchiyama, S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc. Dis. 2009, 27, 485-492.
58. Unno, Y.; Katayama, M.; Shimizu, H. Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy. Clin. Drug Investig. 2010, 30, 143-155.
59. Kimura, K.; Aoki, J.; Sakamoto, Y.; Kobayashi, K.; Sakai, K.; Inoue, T.; Iguchi, Y.; Shibazaki, K. Administration of edaravone, a free radical scavenger, during t-pa infusion can enhance early recanalization in acute stroke patients-A preliminary study. J. Neurol. Sci. 2012, 313, 132-136.
60. Keller, H.; Dreyer, C.; Medin, J.; Mahfoudi, A.; Ozato, K.; Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA 1993, 90, 2160-2164.
61. Elahi, M.; Matata, B. Blood-dependent redox activity during extracorporeal circulation in health and disease. Cardiology 2005, 1, 156-157.
62. Wilson, S.H.; Best, P.J.; Edwards, W.D.; Holmes, D.R., Jr.; Carlson, P.J.; Celermajer, D.S. Lerman, A. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 2002, 160, 147-153.
63. Madamanchi, N.R.; Vendrov, A.; Runge, M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 29-38.
64. Elahi, M.M.; Kong, Y.X.; Matata, B.M. Oxidative stress as a mediator of cardiovascular disease. Oxid. Med. Cell. Longev. 2009, 2, 259-269.
65. Harrison, D.G. Endothelial function and oxidant stress. Clin. Cardiol. 1997, 20, II-11-II-17.
66. Moroi, M.; Zhang, L.; Yasuda, T.; Virmani, R.; Gold, H.K.; Fishman, M.C.; Huang, P.L. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J. Clin. Invest. 1998, 101, 1225-1232.
67. Antoniades, C.; Shirodaria, C.; Warrick, N.; Cai, S.; de Bono, J.; Lee, J.; Leeson, P.; Neubauer, S.; Ratnatunga, C.; Pillai, R., et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114, 1193-1201.
68. Brandes, R.P.; Barton, M.; Philippens, K.M.; Schweitzer, G.; Mugge, A. Endothelial-derived superoxide anions in pig coronary arteries: Evidence from lucigenin chemiluminescence and histochemical techniques. J. Physiol. 1997, 500, 331-342.
69. Lerman, A.; Burnett, J.C., Jr.; Higano, S.T.; McKinley, L.J.; Holmes, D.R., Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998, 97, 2123-2128.
70. Nisoli, E.; Tonello, C.; Cardile, A.; Cozzi, V.; Bracale, R.; Tedesco, L.; Falcone, S.; Valerio, A.; Cantoni, O.; Clementi, E., et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005, 310, 314-317.
71. Radhakrishnan, G.; Suzuki, R.; Maeda, H.; Yamamoto, M.; Hirose, N.; Gopalrao, R.K.; Lee, G.H.; Hayashi, Y.; Rao, P.; Sasaguri, S. Inhibition of neointimal hyperplasia development by MCI-186 is correlated with downregulation of nuclear factor-kappaB pathway. Circ. J. 2008, 72, 800-806.
72. Okabe, T.A.; Kishimoto, C.; Shimada, K.; Murayama, T.; Yokode, M.; Kita, T. Effects of MCI-186 (edaravone), a novel free radical scavenger, upon experimental atherosclerosis in apolipoprotein E-deficient mice. Circ. J. 2006, 70, 1216-1219.
73. Xi, H.; Akishita, M.; Nagai, K.; Yu, W.; Hasegawa, H.; Eto, M.; Kozaki, K.; Toba, K. Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. Atherosclerosis 2007, 191, 281-289.
74. Yamaguchi, T.; Oishi, K.; Uchida, M.; Echizen, H. Edaravone, a radical scavenger, may enhance or produce antiproliferative effects of fluvastatin, amlodipine, ozagrel, GF109203X and Y27632 on cultured basilar artery smooth muscle cells. Biol. Pharm. Bull. 2003, 26, 1706-1710.
75. Oyama, J.; Satoh, S.; Suematsu, N.; Kadokami, T.; Maeda, T.; Sugano, M.; Makino, N. Scavenging free radicals improves endothelial dysfunction in human coronary arteries in vivo. Heart Vessels 2010, 25, 379-385.
76. Berry, J.D.; Dyer, A.; Cai, X.; Garside, D.B.; Ning, H.; Thomas, A.; Greenland, P.; van Horn, L.; Tracy, R.P.; Lloyd-Jones, D.M. Lifetime risks of cardiovascular disease. N. Engl. J. Med. 2012, 366, 321-329.
77. Abou-Seif, M.A.; Youssef, A.A. Oxidative stress and male IGF-1, gonadotropin and related hormones in diabetic patients. Clin. Chem. Lab. Med. 2001, 39, 618-623.
78. Ruiz, C.; Alegria, A.; Barbera, R.; Farre, R.; Lagarda, M.J. Lipid peroxidation and antioxidant enzyme activities in patients with type 1 diabetes mellitus. Scand. J. Clin. Lab. Invest. 1999, 59, 99-105.
79. Christ, M.; Bauersachs, J.; Liebetrau, C.; Heck, M.; Gunther, A.; Wehling, M. Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: Attenuation by the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor atorvastatin. Diabetes 2002, 51, 2648-2652.
80. Guzik, T.J.; West, N.E.; Black, E.; McDonald, D.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ. Res. 2000, 86, E85-E90.
81. Hink, U.; Tsilimingas, N.; Wendt, M.; Munzel, T. Mechanisms underlying endothelial dysfunction in diabetes mellitus: Therapeutic implications. Treat. Endocrinol. 2003, 2, 293-304.
82. Kim, Y.K.; Lee, M.S.; Son, S.M.; Kim, I.J.; Lee, W.S.; Rhim, B.Y.; Hong, K.W.; Kim, C.D. Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 2002, 51, 522-527.
83. Kashiwagi, A.; Shinozaki, K.; Nishio, Y.; Maegawa, H.; Maeno, Y.; Kanazawa, A.; Kojima, H.; Haneda, M.; Hidaka, H.; Yasuda, H., et al. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am. J. Physiol. 1999, 277, E976-E983.
84. Kakkar, R.; Mantha, S.V.; Kalra, J.; Prasad, K. Time course study of oxidative stress in aorta and heart of diabetic rat. Clin. Sci. 1996, 91, 441-448.
85. Marra, G.; Cotroneo, P.; Pitocco, D.; Manto, A.; di Leo, M.A.; Ruotolo, V.; Caputo, S.; Giardina, B.; Ghirlanda, G.; Santini, S.A. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: A case for gender difference. Diabetes Care 2002, 25, 370-375.
86. Saini, A.K.; Patel, R.J.; Sharma, S.S.; Hsarunk, A.K. Edaravone attenuates hydroxyl radical stress and augmented angiotensin ii response in diabetic rats. Pharmacol. Res. 2006, 54, 6-10.
87. Inagi, R. Oxidative stress in cardiovascular disease: A new avenue toward future therapeutic approaches. Recent Pat. Cardiovasc. Drug Discov. 2006, 1, 151-159.
88. Vaziri, N.D.; Wang, X.Q.; Oveisi, F.; Rad, B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 2000, 36, 142-146.
89. Hamilton, C.A.; Brosnan, M.J.; McIntyre, M.; Graham, D.; Dominiczak, A.F. Superoxide excess in hypertension and aging: A common cause of endothelial dysfunction. Hypertension 2001, 37, 529-534.
90. Kerr, S.; Brosnan, M.J.; McIntyre, M.; Reid, J.L.; Dominiczak, A.F.; Hamilton, C.A. Superoxide anion production is increased in a model of genetic hypertension: Role of the endothelium. Hypertension 1999, 33, 1353-1358.
91. Zalba, G.; San Jose, G.; Moreno, M.U.; Fortuno, M.A.; Fortuno, A.; Beaumont, F.J.; Diez, J. Oxidative stress in arterial hypertension: Role of NAD(P)H oxidase. Hypertension 2001, 38, 1395-1399.
92. Koska, J.; Syrova, D.; Blazicek, P.; Marko, M.; Grna, J.D.; Kvetnansky, R.; Vigas, M. Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension. J. Hypertens. 1999, 17, 529-535.
93. Orie, N.N.; Zidek, W.; Tepel, M. Reactive Oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. Am. J. Hypertens. 1999, 12, 1169-1174.
94. Redon, J.; Oliva, M.R.; Tormos, C.; Giner, V.; Chaves, J.; Iradi, A.; Saez, G.T. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003, 41, 1096-1101.
95. Yasunari, K.; Maeda, K.; Nakamura, M.; Yoshikawa, J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002, 39, 777-780.
96. Deshmukh, A.B.; Patel, N.J.; Patel, R.J. Hydroxyl radical mediates the augmented angiotensin II responses in thoracic aorta of spontaneously hypertensive rats. Pharmacology 2007, 79, 122-128.
97. Tsujimoto, I.; Hikoso, S.; Yamaguchi, O.; Kashiwase, K.; Nakai, A.; Takeda, T.; Watanabe, T.; Taniike, M.; Matsumura, Y.; Nishida, K., et al. The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy. Hypertension 2005, 45, 921-926.
98. Ross, R. Atherosclerosis-An inflammatory disease. N. Engl. J. Med. 1999, 340, 115-126.
99. Elkind, M.S. Inflammation, atherosclerosis, and stroke. Neurologist 2006, 12, 140-148.
100. 2-induced apoptosis via MAP Kinase-MKP-1 pathway. Free Radic. Biol. Med. 2004, 36, 985-993.
101. Winyard, P.G.; Blake, D.R. Antioxidants, redox-regulated transcription factors, and inflammation. Adv. Pharmacol. 1997, 38, 403-421.
102. Bonomini, F.; Tengattini, S.; Fabiano, A.; Bianchi, R.; Rezzani, R. Atherosclerosis and oxidative stress. Histol. Histopathol. 2008, 23, 381-390.
103. Harrison, D.; Griendling, K.K.; Landmesser, U.; Hornig, B.; Drexler, H. Role of oxidative stress in stherosclerosis. Am. J. Cardiol. 2003, 91, 7A-11A.
104. Suzuki, Y.J.; Ford, G.D. Redox regulation of signal transduction in cardiac and smooth muscle. J. Mol. Cell. Cardiol.1999, 31, 345-353.
105. Aviram, M.; Rosenblat, M.; Etzioni, A.; Levy, R. Activation of NADPH oxidase required for macrophage-mediated oxidation of low-density lipoprotein. Metabolism 1996, 45, 1069-1079.
106. Chen, X.L.; Tummala, P.E.; Olbrych, M.T.; Alexander, R.W.; Medford, R.M. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ. Res. 1998, 83, 952-959.
107. Griendling, K.K.; Sorescu, D.; Ushio-Fukai, M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ. Res. 2000, 86, 494-501.
108. Cappola, T.P.; Kass, D.A.; Nelson, G.S.; Berger, R.D.; Rosas, G.O.; Kobeissi, Z.A.; Marban, E.; Hare, J.M. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001, 104, 2407-2411.
109. Heymes, C.; Bendall, J.K.; Ratajczak, P.; Cave, A.C.; Samuel, J.L.; Hasenfuss, G.; Shah, A.M. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll. Cardiol. 2003, 41, 2164-2171.
110. Ghafourifar, P.; Asbury, M.L.; Joshi, S.S.; Kincaid, E.D. Determination of mitochondrial nitric oxide synthase activity. Methods Enzymol. 2005, 396, 424-444.
111. Maytin, M.; Siwik, D.A.; Ito, M.; Xiao, L.; Sawyer, D.B.; Liao, R.; Colucci, W.S. Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox. Circulation 2004, 109, 1168-1171.
112. Jolly, S.R.; Kane, W.J.; Bailie, M.B.; Abrams, G.D.; Lucchesi, B.R. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ. Res. 1984, 54, 277-285.
113. Onogi, H.; Minatoguchi, S.; Chen, X.H.; Bao, N.; Kobayashi, H.; Misao, Y.; Yasuda, S.; Yamaki, T.; Maruyama, R.; Uno, Y., et al. Edaravone reduces myocardial infarct size and improves cardiac function and remodelling in rabbits. Clin. Exp. Pharmacol. Physiol. 2006, 33, 1035-1041.
114. Nakamura, Y.; Yamada, Y.; Shimomura, H.; Nagayoshi, Y.; Tsujita, K.; Yamashita, T.; Fukuda, M.; Ohba, K.; Nako, H.; Ogura, Y., et al. Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. J. Cardiol. 2009, 54, 416-424.
115. Tsujita, K.; Shimomura, H.; Kaikita, K.; Kawano, H.; Hokamaki, J.; Nagayoshi, Y.; Yamashita, T.; Fukuda, M.; Nakamura, Y.; Sakamoto, T., et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ. J. 2006, 70, 832-837.
116. Jurewicz, M.; Ueno, T.; Azzi, J.; Tanaka, K.; Murayama, T.; Yang, S.; Sayegh, M.H.; Niimi, M.; Abdi, R. Donor antioxidant strategy prolongs cardiac allograft survival by attenuating tissue dendritic cell immunogenicity. Am. J. Transplant. 2011, 11, 348-355.
117. Kotani, Y.; Ishino, K.; Osaki, S.; Honjo, O.; Suezawa, T.; Kanki, K.; Yutani, C.; Sano, S. Efficacy of MCI-186, a free-radical scavenger and antioxidant, for resuscitation of nonbeating donor hearts. J. Thorac. Cardiovasc. Surg. 2007, 133, 1626-1632.
118. Yamazaki, K.; Miwa, S.; Toyokuni, S.; Nemoto, S.; Oriyanhan, W.; Takaba, K.; Saji, Y.; Marui, A.; Nishina, T.; Ikeda, T., et al. Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: In vitro study of isolated rat heart. Heart Vessels 2009, 24, 228-235.
119. Minhaz, U.; Tanaka, M.; Tsukamoto, H.; Watanabe, K.; Koide, S.; Shohtsu, A.; Nakazawa, H. Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart. Free Radic. Res. 1996, 24, 361-367.
120. Wu, T.W.; Zeng, L.H.; Wu, J.; Fung, K.P. Myocardial protection of MCI-186 in rabbit ischemia-reperfusion. Life Sci. 2002, 71, 2249-2255.
121. Yagi, H.; Horinaka, S.; Matsuoka, H. Edaravone prevented deteriorated cardiac function after myocardial ischemia-reperfusion via inhibiting lipid peroxidation in rat. J. Cardiovasc. Pharmacol. 2005, 46, 46-51.
122. Rajesh, K.G.; Sasaguri, S.; Suzuki, R.; Maeda, H. Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates bcl-2 expression. Am. J. Physiol. Heart Circ. Physiol. 2003,285, H2171-2178.121.
123. Onimaru, S.; Nakamura, K.; Kariyazono, H.; Ikeda, R.; Ueno, T.; Fukumoto, Y.; Yabuki, A.; Sakata, R.; Yamada, K. Inhibitory effects of edaravone on the production of tumor necrosis factor-alpha in the isolated heart undergoing ischemia and reperfusion. Heart Vessels 2006, 21, 108-115.
124. Pei, H.; Jia, M.; Sun, L.; Zheng, X.; Zhou, H. A hypothesis: Edaravone exert cardioprotection partly via modulation of adiponectin. Med. Hypotheses 2012, 79, 141-142.
125. Sukmawan, R.; Yada, T.; Toyota, E.; Neishi, Y.; Kume, T.; Shinozaki, Y.; Mori, H.; Ogasawara, Y.; Kajiya, F.; Yoshida, K. Edaravone preserves coronary microvascular endothelial function after ischemia/reperfusion on the beating canine heart in vivo. J. Pharmacol. Sci. 2007, 104, 341-348.
126. Miyazaki, Y.; Kaikita, K.; Endo, M.; Horio, E.; Miura, M.; Tsujita, K.; Hokimoto, S.; Yamamuro, M.; Iwawaki, T.; Gotoh, T., et al. C/EBP homologous protein deficiency attenuates myocardial reperfusion injury by inhibiting myocardial apoptosis and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1124-1132.
127. Fukuda, A.; Okubo, S.; Tanabe, Y.; Hoshiba, Y.; Shiobara, H.; Harafuji, K.; Kobori, Y.; Fujinawa, M.; Okubo, T.; Yamashina, A. Cardioprotective effect of edaravone against ischaemia-reperfusion injury in the rabbit heart before, during and after reperfusion treatment. J. Int. Med. Res. 2006,34, 475-484.
128. Walker, J.R.; Fairfull-Smith, K.E.; Anzai, K.; Lau, S.; White, P.J.; Scammells, P.J.; Bottle, S.E. Edaravone containing isoindoline nitroxides for the potential treatment of cardiovascular ischaemia. Med. Chem. Commun. 2011, 2, 436-441.
129. Sorescu, D.; Griendling, K.K. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest. Heart Fail. 2002, 8, 132-140.
130. Nakamura, K.; Fushimi, K.; Kouchi, H.; Mihara, K.; Miyazaki, M.; Ohe, T.; Namba, M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998, 98, 794-799.
131. Zafari, A.M.; Ushio-Fukai, M.; Akers, M.; Yin, Q.; Shah, A.; Harrison, D.G.; Taylor, W.R.; Griendling, K.K. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998, 32, 488-495.
132. Li, J.M.; Gall, N.P.; Grieve, D.J.; Chen, M.; Shah, A.M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002, 40, 477-484.
133. Ekelund, U.E.; Harrison, R.W.; Shokek, O.; Thakkar, R.N.; Tunin, R.S.; Senzaki, H.; Kass, D.A.; Marban, E.; Hare, J.M. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ. Res. 1999, 85, 437-445.
134. Ide, T.; Tsutsui, H.; Kinugawa, S.; Utsumi, H.; Kang, D.; Hattori, N.; Uchida, K.; Arimura, K.; Egashira, K.; Takeshita, A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 1999, 85, 357-363.
135. Grocott-Mason, R.; Anning, P.; Evans, H.; Lewis, M.J.; Shah, A.M. Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide. Am. J. Physiol. 1994, 267, H1804-H1813.
136. Ferdinandy, P.; Danial, H.; Ambrus, I.; Rothery, R.A.; Schulz, R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ. Res. 2000, 87, 241-247.
137. 2+-ATPase in low-frequency stimulated rabbit muscle. FEBS Lett. 1998, 422, 381-384.
138. Maack, C.; Kartes, T.; Kilter, H.; Schafers, H.J.; Nickenig, G.; Bohm, M.; Laufs, U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-gtpase and represents a target for statin treatment. Circulation 2003, 108, 1567-1574.
139. De Biase, L.; Pignatelli, P.; Lenti, L.; Tocci, G.; Piccioni, F.; Riondino, S.; Pulcinelli, F.M.; Rubattu, S.; Volpe, M.; Violi, F. Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of tnf alpha on platelet O2-production. Thromb. Haemost. 2003, 90, 317-325.
140. Belch, J.J.; Bridges, A.B.; Scott, N.; Chopra, M. Oxygen free radicals and congestive heart failure. Br. Heart J. 1991, 65, 245-248.
141. Yano, M.; Okuda, S.; Oda, T.; Tokuhisa, T.; Tateishi, H.; Mochizuki, M.; Noma, T.; Doi, M.; Kobayashi, S.; Yamamoto, T., et al. Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 2005, 112, 3633-3643.
142. Xin, Y.; Zhang, S.; Gu, L.; Liu, S.; Gao, H.; You, Z.; Zhou, G.; Wen, L.; Yu, J.; Xuan, Y. Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs. Biol. Pharm. Bull. 2011, 34, 1523-1526.
143. Arumugam, S.; Thandavarayan, R.A.; Veeraveedu, P.T.; Nakamura, T.; Arozal, W.; Sari, F.R.; Giridharan, V.V.; Soetikno, V.; Palaniyandi, S.S.; Harima, M., et al. Beneficial effects of edaravone, a novel antioxidant, in rats with dilated cardiomyopathy. J. Cell. Mol. Med. 2012, 16, 2176-2185.
144. Watanabe, K.; Sukumaran, V.; Veeraveedu, P.T.; Thandavarayan, R.A.;
145. Okabe, T.A.; Kishimoto, C.; Hattori, M.; Nimata, M.; Shioji, K.; Kita, T. Cardioprotective effects of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), a novel free radical scavenger, on acute autoimmune myocarditis in rats. Exp. Clin. Cardiol. 2004, 9, 177-180.
146. Pryor, W.A. The antioxidant nutrients and disease prevention-What do we know and what do we need to find out? Am. J. Clin. Nutr. 1991, 53, 391S-393S.
147. Nimata, M.; Okabe, T.A.; Hattori, M.; Yuan, Z.; Shioji, K.; Kishimoto, C. MCI-186 (edaravone), a novel free radical scavenger, protects against acute autoimmune myocarditis in rats. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H2514-H2518.
148. Shimazaki, H.; Watanabe, K.; Veeraveedu, P.T.; Harima, M.; Thandavarayan, R.A.; Arozal, W.; Tachikawa, H.; Kodama, M.; Aizawa, Y. The antioxidant edaravone attenuates er-stress-mediated cardiac apoptosis and dysfunction in rats with autoimmune myocarditis. Free Radic. Res. 2010, 44, 1082-1090.
149. Arumugam, S.; Thandavarayan, R.A.; Veeraveedu, P.T.; Giridharan, V.V.; Soetikno, V.; Harima, M.; Suzuki, K.; Nagata, M.; Tagaki, R.; Kodama, M., et al. Involvement of AMPK and MAPK signaling during the progression of experimental autoimmune myocarditis in rats and its blockade using a novel antioxidant. Exp. Mol. Pathol. 2012, 93, 183-189.
150. Yamawaki, M.; Sasaki, N.; Shimoyama, M.; Miake, J.; Ogino, K.; Igawa, O.; Tajima, F.; Shigemasa, C.; Hisatome, I. Protective effect of edaravone against hypoxia-reoxygenation injury in rabbit cardiomyocytes. Br. J. Pharmacol. 2004, 142, 618-626.